DK0626969T3 - CoA-IT- og PAF-inhibitorer - Google Patents
CoA-IT- og PAF-inhibitorerInfo
- Publication number
- DK0626969T3 DK0626969T3 DK93905896T DK93905896T DK0626969T3 DK 0626969 T3 DK0626969 T3 DK 0626969T3 DK 93905896 T DK93905896 T DK 93905896T DK 93905896 T DK93905896 T DK 93905896T DK 0626969 T3 DK0626969 T3 DK 0626969T3
- Authority
- DK
- Denmark
- Prior art keywords
- coa
- production
- arachidonic acid
- paf inhibitors
- coenzyme
- Prior art date
Links
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 title 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 abstract 1
- 101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 abstract 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 229940114079 arachidonic acid Drugs 0.000 abstract 1
- 235000021342 arachidonic acid Nutrition 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005516 coenzyme A Substances 0.000 abstract 1
- 229940093530 coenzyme a Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000010118 platelet activation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83385092A | 1992-02-11 | 1992-02-11 | |
| US83388092A | 1992-02-11 | 1992-02-11 | |
| US83387792A | 1992-02-11 | 1992-02-11 | |
| US83404892A | 1992-02-11 | 1992-02-11 | |
| US83387892A | 1992-02-11 | 1992-02-11 | |
| US83387992A | 1992-02-11 | 1992-02-11 | |
| GB929202827A GB9202827D0 (en) | 1992-02-11 | 1992-02-11 | Compounds |
| PCT/US1993/001247 WO1993016674A1 (en) | 1992-02-11 | 1993-02-11 | CoA-IT AND PAF INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0626969T3 true DK0626969T3 (da) | 2000-10-30 |
Family
ID=27562876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93905896T DK0626969T3 (da) | 1992-02-11 | 1993-02-11 | CoA-IT- og PAF-inhibitorer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5648373A (da) |
| EP (1) | EP0626969B1 (da) |
| JP (1) | JP2001527506A (da) |
| KR (2) | KR100291112B1 (da) |
| AT (1) | ATE193290T1 (da) |
| AU (2) | AU3664593A (da) |
| CA (1) | CA2129897C (da) |
| DE (1) | DE69328716T2 (da) |
| DK (1) | DK0626969T3 (da) |
| ES (1) | ES2149201T3 (da) |
| GR (1) | GR3034040T3 (da) |
| PT (1) | PT626969E (da) |
| WO (1) | WO1993016674A1 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11511130A (ja) * | 1995-07-25 | 1999-09-28 | スミスクライン・ビーチャム・コーポレイション | ＣｏＡ−非依存性トランスアシラーゼの阻害およびアポトーシス |
| US6083949A (en) * | 1995-10-06 | 2000-07-04 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| EP0956018A4 (en) * | 1996-08-21 | 2000-01-12 | Smithkline Beecham Corp | IMIDAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE |
| EA003095B1 (ru) * | 1997-12-17 | 2002-12-26 | Мерк Энд Ко., Инк. | Антагонисты рецепторов интегринов |
| GB9904895D0 (en) * | 1999-03-03 | 1999-04-28 | Scarista Limited | Regulators of coenzyme-A-independent transacylase as psychotropic drugs |
| US20030096854A1 (en) * | 2002-06-12 | 2003-05-22 | Ho-Shen Lin | Substituted tricyclics |
| EP1506966A3 (en) * | 2001-03-26 | 2005-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystaline structures thereof |
| BR0208462A (pt) * | 2001-03-26 | 2004-03-02 | Ortho Mcneil Pharm Inc | Processo para a preparação de derivados imidazólicos e novas estruturas cristalinas dos mesmos |
| FR2823751B1 (fr) * | 2001-04-24 | 2003-05-23 | Oreal | Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires |
| FR2823747B1 (fr) * | 2001-04-24 | 2003-05-23 | Oreal | Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires |
| WO2002087569A1 (en) | 2001-04-27 | 2002-11-07 | Bristol-Myers Squibb Company | Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
| US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7323485B2 (en) * | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
| TW200505446A (en) * | 2003-01-17 | 2005-02-16 | Fuj Isawa Pharmaceutical Co Ltd | Inhibitor of cox |
| EP2015638A4 (en) * | 2006-04-28 | 2010-09-29 | Redpoint Bio Corp | TRIARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS TASTE INHIBITORS |
| WO2008140251A2 (en) * | 2007-05-14 | 2008-11-20 | University-Industry Cooperation Group Of Kyung Hee University | Cyclooxygenase-2 inhibitors |
| US11970460B1 (en) | 2023-10-24 | 2024-04-30 | King Faisal University | 4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound |
| US11999703B1 (en) | 2023-10-25 | 2024-06-04 | King Faisal University | 5-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound |
| US11939298B1 (en) * | 2023-10-25 | 2024-03-26 | King Faisal University | 5-(4,5-bis(4-bromophenyl)-2-(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound |
| US11945783B1 (en) | 2023-10-26 | 2024-04-02 | King Faisal University | 4-(4,5-bis(4-bromophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)butanoic acid as an antimicrobial compound |
| US11932607B1 (en) | 2023-10-27 | 2024-03-19 | King Faisal University | 4-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3021338A (en) * | 1956-12-05 | 1962-02-13 | Rohm & Haas | Adducts of heterocyclic amides |
| CH633779A5 (de) * | 1977-07-07 | 1982-12-31 | Ciba Geigy Ag | Verfahren zur herstellung neuer vinylaether und deren verwendung zur herstellung von polymeren. |
| DE2823197A1 (de) * | 1978-05-24 | 1979-11-29 | Schering Ag | Neue imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| DE3228271A1 (de) * | 1982-07-29 | 1984-02-02 | A. Nattermann & Cie GmbH, 5000 Köln | Triphenylimidazolyloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| US5248689A (en) * | 1989-11-06 | 1993-09-28 | Smithkline Beecham Corporation | Substituted N-(imidazolyl)alkyl alanine derivatives |
| GB9019839D0 (en) * | 1990-09-11 | 1990-10-24 | Smith Kline French Lab | Compounds |
| US5087634A (en) * | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
| US5256695A (en) * | 1991-07-24 | 1993-10-26 | E. R. Squibb & Sons, Inc. | Acyl amidine and acyl guanidine substituted biphenyl derivatives |
-
1993
- 1993-02-11 ES ES93905896T patent/ES2149201T3/es not_active Expired - Lifetime
- 1993-02-11 JP JP51489693A patent/JP2001527506A/ja not_active Ceased
- 1993-02-11 EP EP93905896A patent/EP0626969B1/en not_active Expired - Lifetime
- 1993-02-11 CA CA002129897A patent/CA2129897C/en not_active Expired - Fee Related
- 1993-02-11 PT PT93905896T patent/PT626969E/pt unknown
- 1993-02-11 DK DK93905896T patent/DK0626969T3/da active
- 1993-02-11 AU AU36645/93A patent/AU3664593A/en not_active Abandoned
- 1993-02-11 KR KR1019940702793A patent/KR100291112B1/ko not_active Expired - Fee Related
- 1993-02-11 AT AT93905896T patent/ATE193290T1/de not_active IP Right Cessation
- 1993-02-11 DE DE69328716T patent/DE69328716T2/de not_active Expired - Fee Related
- 1993-02-11 WO PCT/US1993/001247 patent/WO1993016674A1/en not_active Ceased
- 1993-08-06 US US08/102,877 patent/US5648373A/en not_active Expired - Fee Related
- 1993-11-02 KR KR1020007011694A patent/KR100365913B1/ko not_active Expired - Fee Related
-
1997
- 1997-10-17 AU AU41867/97A patent/AU701541B2/en not_active Ceased
-
2000
- 2000-07-27 GR GR20000401730T patent/GR3034040T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR950700734A (ko) | 1995-02-20 |
| EP0626969A1 (en) | 1994-12-07 |
| US5648373A (en) | 1997-07-15 |
| EP0626969A4 (en) | 1995-04-19 |
| WO1993016674A1 (en) | 1993-09-02 |
| CA2129897A1 (en) | 1993-08-12 |
| AU701541B2 (en) | 1999-01-28 |
| DE69328716T2 (de) | 2000-11-23 |
| AU4186797A (en) | 1998-01-08 |
| CA2129897C (en) | 2006-01-10 |
| JP2001527506A (ja) | 2001-12-25 |
| ATE193290T1 (de) | 2000-06-15 |
| KR100365913B1 (ko) | 2002-12-26 |
| KR100291112B1 (ko) | 2001-09-17 |
| DE69328716D1 (de) | 2000-06-29 |
| EP0626969B1 (en) | 2000-05-24 |
| AU703236B2 (en) | 1999-03-18 |
| AU3664593A (en) | 1993-09-13 |
| AU6482698A (en) | 1998-07-16 |
| GR3034040T3 (en) | 2000-11-30 |
| PT626969E (pt) | 2000-11-30 |
| ES2149201T3 (es) | 2000-11-01 |
| HK1013421A1 (en) | 1999-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE193290T1 (de) | Coa-it- und paf-inhibitoren | |
| TR200102399T2 (tr) | Tiyoamid türevleri | |
| TR200401545T4 (tr) | NOSS inhibitörü ilaçların amalatı için ikame imidazo [1,2-a]piridin-,-pirimidin- ve-pirazin-3-amin-türevlerinin kullanımı | |
| DK1119362T3 (da) | Anvendelse af tetracyclinderivater til forögelse af interleukin-10-produktion | |
| GB0025670D0 (en) | Preparation for the relief of inflammatory disease | |
| DK1030836T3 (da) | Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet | |
| ATE215366T1 (de) | 3-benzoylphenylessigsäure-derivate enthaltende topische zusammensetzungen zur behandlung der ophthalmischen entzündungserkrankungen | |
| BG101130A (bg) | Инхибитори на интерлевкин 1 бета-конвертиращ ензим | |
| DE69531864D1 (de) | Indolizin spal2 inhibitoren | |
| EP1349562A4 (en) | INHIBITION OF GS-FDH TO MODULATE NO-BIOACTIVITY | |
| DK1137416T3 (da) | Anvendelse af langkædede N-alkylderivater af deoxynojirimycin til fremstilling af et lægemiddel til behandling af glycolipidophobnings-sygdomme | |
| ATE284860T1 (de) | Neue verwendung von phenylheteroalkylamin- derivaten | |
| NO983992L (no) | Serinprotease inhibitorer | |
| DE69935720D1 (de) | Diamino-propanol-verbindungen zur behandlung von ischaemien | |
| NI200400073A (es) | Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide | |
| NO983991L (no) | Serin-protease-inhibitorer | |
| DK0782441T3 (da) | Farmaceutisk kontrol af inflammation | |
| ATE311191T1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
| IT1318667B1 (it) | Medicamento antinfiammatorio. | |
| IT1263957B (it) | Impiego terapeutico del pirrolidon carbossilato di piridossina | |
| NO993627L (no) | Anvendelse av en forbindelse for fremstilling av et legemiddel | |
| RU2001120358A (ru) | Применение ингибиторов натрий-водород-антипортера для получения лекарственного средства для ингибирования обусловленных возрастом дисфункций органов, обусловленных возрастом заболеваний и для продления жизни | |
| ES2056983T3 (es) | Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa. | |
| NO20032006D0 (no) | Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser | |
| ATE350367T1 (de) | Spla2 inhibitoren |